Genmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024. In the quarter to June 2026, revenue grew 24.9%, EPS fell 9.26% and free cash flow fell 7.69%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow GMAB
Genmab A/S Sponsored ADR (GMAB) EV/Sales
As of 16 October 2026, Genmab A/S Sponsored ADR (GMAB) trades at a EV/Sales of 6.4×. Over the past ten years it has ranged from 0.0× (September 2019) to 24.8× (December 2019); the current reading is higher than 44% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.1× | 80.45% |
| FY2024 | 3.4× | (52.41%) |
| FY2023 | 7.1× | (41.40%) |
| FY2022 | 12.1× | (28.41%) |
| FY2021 | 16.9× | 8.91% |
| FY2020 | 15.6× | 0.54% |
| FY2019 | 15.5× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.0× | (6.18%) |
| Mar 2026 | 5.3× | (13.40%) |
| Dec 2025 | 6.1× | 40.30% |
| Sep 2025 | 4.3× | 47.36% |
| 27 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 1.8× |
| INCY Incyte Corporation compare | 3.1× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 6.0× |
| EXEL Exelixis, Inc. compare | 6.1× |
| GMAB Genmab A/S Sponsored ADR | 6.4× |
| ASND Ascendis Pharma A/S compare | 11.6× |
| RPRX Royalty Pharma PLC compare | 14.0× |
| INSM Insmed, Inc. compare | 18.1× |
| ROIV Roivant Sciences Ltd. compare | 2,742× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)